Teriflunomide
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Teriflunomide. Teriflunomide inhibits activated T and B cells. It inhibits the enzyme dihydroorotate dehydrogenase. Fully referenced neurology checklist.
Mode of action and dosage
- Teriflunomide inhibits activated T and B cells
- It inhibits the enzyme dihydroorotate dehydrogenase
- In this way it inhibits pyrimidine synthesis in proliferating lymphocytes
- The dose is 14mg daily PO
Haematological side effects
Locked: subscribe to see this section.
Infectious side effects
Locked: subscribe to see this section.
Hepatic side effects
Locked: subscribe to see this section.
Neuromuscular side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
Monitoring: liver function tests
Locked: subscribe to see this section.
Monitoring: other tests
Locked: subscribe to see this section.
Teriflunomide and pregnancy
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5:205-220.
- Rice CM. Disease modification in multiple sclerosis: an update. Pract Neurol 2014; 14:6-13.
- Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Neurol 2014; 13:247–256.
- Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:977–986.
- And 13 more. Subscribe to see the full list
